Chest
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (12)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stockley, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stockley, R. A.
(Chest. 2000;117:58S-62S.)
© 2000 American College of Chest Physicians

New Approaches to the Management of COPD*

Robert A. Stockley, MD, DSc

* From the Department of Medicine, Queen Elizabeth Hospital, Birmingham, UK.

Correspondence to: Robert A. Stockley, MD, DSc, Department of Medicine, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, UK

Airflow limitation in COPD is a result partially of bronchospasm, but it is also caused by a reduction in airway caliber, the number of small airways, airway collapse because of loss of connective tissue support, excess mucus in the airways, and edema of the airway wall. Structural changes also occur because of long-term destruction of interstitial connective tissue, including elastin. Therefore, in addition to the traditional aim of reversing bronchospasm with bronchodilators, disease-modifying approaches are being investigated. The enzyme neutrophil elastase is implicated in the induction of bronchial disease causing structural changes in lungs, impairment of mucociliary clearance, and impairment of host defenses. The precise mechanism pathway of neutrophil elastase is uncertain, but the effects of influencing the pathway in order to slow disease progression are being investigated. Oxidants may also have a role in the development of COPD, with increased levels activating airway cells and cytokine production.

Key Words: antiproteases • COPD • inflammation • neutrophil elastase • neutrophils




This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
J. A Dougherty, B. L Didur, and L. S Aboussouan
Long-Acting Inhaled {beta}2-Agonists for Stable COPD
Ann. Pharmacother., September 1, 2003; 37(9): 1247 - 1255.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. J. Ancliff, R. E. Gale, R. Liesner, I. M. Hann, and D. C. Linch
Mutations in the ELA2 gene encoding neutrophil elastase are present in most patients with sporadic severe congenital neutropenia but only in some patients with the familial form of the disease
Blood, November 1, 2001; 98(9): 2645 - 2650.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
P.J. Grant
The Edinburgh Artery Study: is lytic activity bad for the heart?
Eur. Heart J., October 1, 2000; 21(19): 1566 - 1567.
[PDF]

eLetters:

Read all eLetters

Managament of COPD
S K Agarwal
Chest Online, 23 Feb 2001 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American College of Chest Physicians.